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Abstract
Background: Reports on the state of knowledge about medicines and driving showed an increased concern
about the role that the use of medicines might play in car crashes. Much of patient knowledge regarding
medicines comes from communications with healthcare professionals. This study, part of the DRUID (Driving Under
the Influence of Drugs, alcohol and medicines) project, was carried out in four European countries and attempts to
define predictors for knowledge of patients who use driving-impairing medicines. The influence of socio-
demographic variables on patient knowledge was investigated as well as the influence of socio-demographic
factors, knowledge and attitudes on patients’ reported behaviour regarding driving under the influence of
medicines.
Methods: Pharmacists handed out questionnaires to patients who met the inclusion criteria: 1) prevalent user of
benzodiazepines, antidepressants or first generation antihistamines for systemic use; 2) age between 18 and 75
years old and 3) actual driver of a motorised vehicle. Factors affecting knowledge and reported behaviour towards
driving-impairing medicines were analysed by means of multiple linear regression analysis and multiple logistic
regression analysis, respectively.
Results: A total of 633 questionnaires (out of 3.607 that were distributed to patients) were analysed. Patient
knowledge regarding driving under the influence of medicines is better in younger and higher educated patients.
Information provided to or accessed by patients does not influence knowledge. Patients who experienced side
effects and who have a negative attitude towards driving under the influence of impairing medicines are more
prone to change their driving frequency behaviour than those who use their motorised vehicles on a daily basis or
those who use anti-allergic medicines.
Conclusions: Changes in driving behaviour can be predicted by negative attitudes towards driving under the
influence of medicines but not by patients’ knowledge regarding driving under the influence of medicines. Future
research should not only focus on information campaigns for patients but also for healthcare providers as this
might contribute to improve communications with patients regarding the risks of driving under the influence of
medicines.
Background
It has been known for many years that the consumption
of psychoactive substances, such as alcohol, sedatives,
anxiolytics, antidepressants or illicit drugs, has a negative
effect on the ability to drive [1]. In fact, either alone or in
combination, alcohol and psychoactive substances
increase the risk of having a traffic accident [1-7].
According to the European Commission’s Directorate-
General for Mobility and Transport, Road Safety Unit,
25% of accidents involve alcohol, medicines, or illicit
drugs. These accidents are directly responsible for the
loss of 10.000 lives due to car crashes in Europe every
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a great amount of money and effort in changing the
behaviour of road users not only with respect to the use
of seat belts and speed limits but also towards driving
under the influence of alcohol, illicit drugs and medi-
cines. Despite all the attempts and all the road safety
campaigns that have been launched, traffic accidents are
still responsible for more than 40,000 deaths and 1.7 mil-
lion injuries across Europe [9].
Therefore, special efforts are needed in order to have a
better knowledge of the various aspects of this specific
problem and to develop appropriate solutions. This is
the reason why an EU-project under the acronym of
DRUID (Driving under the Influence of Drugs, Alcohol
and Medicines) [10] was funded by the European Com-
mission. DRUID aims not only to improve the possibili-
ties of detecting drug-influenced driving in Europe but
also to combat the scourge of drunk-driving and find
answers to the question of the use of drugs or medicines
that affect people’s ability to drive safely
Reports on the state of knowledge about drugs and
driving [1] showed an increased concern about the role
that the use of medicines might play in traffic accidents.
It has been estimated that 5-10% of medicines impair
driving performance [2] as a consequence of their effects
or side effects. This is the reason why it is so important
to inform drivers who use driving-impairing medicines
of the risks of driving under the influence. Research
conducted in European countries has shown that
patients do want to be informed about their medicines,
their risks [11] and side-effects [11-13]. Similarly, in the
U.S., two-thirds of patients reported the desire to be
informed of all possible side effects of their medicines
[14]. Much of patient knowledge regarding their medi-
cines comes from communication with healthcare pro-
fessionals, such as general practitioners and pharmacists,
media exposure, and reading the safety information on
the medicine’s label [15]. Age and educational level
seem to influence patient awareness and knowledge as
health literacy decreases with increasing age [15].
In order to better understand and predict human beha-
viour, some theories have been derived to describe and
explain how and why people behave the way they do.
T h et h e o r yo fp l a n n e db e h a v i o u r( T P B ) ,t h et h e o r yo f
interpersonal behaviour (TIB), and other more recent
models with direct application in health research are
examples of what has been done in the field of predictive
behaviour. TBP was first suggested by Fishbein and
Ajzen [16] and TIB is an extension of TBP. Both theories
focus on intentions that are personal decisions to per-
form behaviour and are based on someone’sk n o w l e d g e
about themselves and about the world around them. In
TBP, intensions are based on attitudes towards the beha-
viour, subjective norms, and perceived behaviour control.
These three aspects form an intention that, ultimately,
leads to a behaviour. TIB, on the other hand, integrates
normative and social factors into TBP. In this theory,
perceived consequences of behaviour and habits are pre-
dictors of intentions that, like in the TBP, lead to beha-
viour. It might be true that influencing attitudes do not
always result in a change of behaviour. Nevertheless,
recent studies state that attitude is linked to traffic viola-
tions, especially when related to speed limits violations
[17], use of seat belts [18], and driving under the influ-
ence of alcohol.
Having the TBP and TIB as a main reference, this
research attempts to determine predictors that can
influence not only patients’ reported behaviour, but also
their knowledge. In a simplified way, the theoretical rea-
soning behind the construction of the models was based
on the assumption that socio-demographic characteris-
tics play a central role in knowledge (evaluated as
knowledge about risk of having a traffic accident). Both
socio-demographic characteristics and knowledge in
combination with attitudes, defined as feelings towards
driving under the influence of medicines, were used to
predict reported behavior (in terms of change in driving
frequency and/or in terms of change in the use of medi-
cines). Figure 1 exemplifies the model that was devel-
oped based upon mentioned theoretical insights. The
present study is part of DRUID, and it was conducted in
4 countries.
Methods
Design
The study was conducted in four countries: Belgium,
Germany, Spain and the Netherlands, in 2007. The
reason why these four countries were selected is
because the Ministry of Transport or the national
organization of pharmacists developed materials
related to drugs and driving, and, therefore, they were
very sensitive to the topic and, as a consequence, more
willing to participate.
Figure 1 Theoretical model to determine predictors for patient
knowledge and reported behavior.
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a previous Dutch national survey [19]. The original
questionnaire was constructed by a multi-disciplinary
team of experts and tested in over a 1000 consumers
and patients.
Patients received the questionnaire through their
pharmacy. Pharmacists were asked to hand out a ques-
tionnaire to approximately 1.000 patients (per country)
who went to a community pharmacy and met the estab-
lished inclusion criteria (see below).
The study was approved by the Medical Ethical Com-
mittee of the Universitair Medisch Centrum Groningen
(University Medical Centre Groningen), the Netherlands
as well as by the Medical Ethics Committee of the Univer-
sidad de Valladolid (Spain) and Ghent University Hospital
Medical Ethics Committee (Belgium). Patient anonymity
was ensured and all data were kept confidential.
Pharmacies
Different approaches were used to select the pharmacies,
depending on the country.
Belgium
In Belgium, only Flemish pharmacies were approached. A
message was spread through the APB (Algemene Phar-
maceutische Bond–Belgian Pharmaceutical Association)
and Escapo (an authorised wholesaler) to a selected num-
ber of pharmacies (93 in total). A total of 40 pharmacies
(43% response rate) agreed to participate in the study.
Germany
In collaboration with ABDA (Bundesvereinigung
Deutscher Apothekerverbände–Federal Union of German
Associations of Pharmacists), a total of 3.600 pharmacies,
part of the ABDA network, were invited to participate in
the study, from which 38 pharmacies (1% response rate)
accepted the invitation.
The Netherlands
The pharmacies invited to participate in the Dutch patient
questionnaires were selected among all the pharmacies
that already cooperated with the University of Groningen,
Pharmacy (RuG-Pha). Pharmacies that were participating
in on-going projects were excluded. A total of 93 pharma-
cies were invited to participate in the study and 36 phar-
macies (39% response rate) accepted the invitation.
Spain
In Spain, the institute responsible for the dissemination of
the questionnaires was the University of Valladolid (UVa),
in collaboration with the Spanish Society of Community
pharmacies (Sociedad Espańola de Farmacia Comunitaria).
Nationalwise, a total of 80 pharmacies were invited to par-
ticipate. Of these, 35 (44% response rate) were actually
enrolled in the study.
Pharmacists who agreed to participate in this study were
not trained for this study. Yet, all participating pharmacists
were provided with detailed information about the study,
which included a list of participant inclusion criteria trans-
lated into the national language of each country. The relia-
bility of the method to select patients was assured by
addressing questions covering the inclusion criteria in the
questionnaire and by excluding the patient from the analy-
sis whenever the inclusion criteria was not fulfilled. Phar-
macists looked for potential participants during working
hours for a period of 3 weeks.
Patient inclusion criteria
Patients were eligible to participate in the study if they
met the following inclusion criteria:
1. The patient uses anyone of the following medicines
that are known to impair driving ability:
2. The patient is a prevalent user (2nd prescription or
more); ensuring that they experienced any possible side
effects and resulting changes in reported behaviour.
3. The patient is 18-75 years of age, as it is known to
be the age group that actively participates in driving and
that takes medicines.
4. The patient actually drives a motorised vehicle in
traffic (is to be asked at the time of dispensing).
￿ Benzodiazepines (as hypnotic or anxiolytic): flunitra-
zepam, flurazepam, loprazolam, nitrazepam, zopiclon,
alprazolam, bromazepam, buspirone (> 2dd 10 mg),
chlordiazepoxide, diazepam, lorazepam, oxazepam.
￿ Antihistamines (1st generation antihistamines): clem-
astine, dexchlorpheniramine, promethazine, cyprohepta-
dine, tripelennamine, hydroxyzine.
￿ Antihistamines (1st generation antihistamines): clem-
astine, dexchlorpheniramine, promethazine, cyprohepta-
dine, tripelennamine, hydroxyzine.
When the patient met the four criteria mentioned above,
he/she was asked to participate in the survey. A patient
information letter, a paper questionnaire, and a stamped
addressed return envelope were given to patients who
agreed to participate in the study. Participants filled in the
questionnaire at home and no information on the time for
completion of the questionnaire was asked.
Non-respondents
No records on the non-respondents were kept. This
methodological decision was made for a practical reason
based on the extra administrative work that pharmacists
would have to do, which would have drastically decreased
the number of pharmacists enrolled in the study. As a
consequence, it is not possible to correlate participants’
refusal patterns with time consumed filling in the ques-
tionnaire, age, gender, or any other socio-demographic
variable.
Questionnaire
The questionnaire was developed in English and, after
consensus about the content, it was translated into the
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decided to use only a Dutch version for Belgium). There-
after, reverse translation back into English was performed
to ensure consistency between the translations.
The questionnaire consisted of 43 questions (39 closed
questions and 4 open questions). The questions were
grouped into 6 topics of interest covering general informa-
tion (including information related with the inclusion cri-
teria), participation in traffic, medicines in traffic, use of
medicines, information about medicines, and attitude
towards reported behaviour in traffic. By doing so, it was
possible to collect data on general items regarding the
patient characteristics as a participant in traffic and about
patients medicine use. Specific items to assess patient
knowledge, attitude, and reported behaviour were gathered
as well. The questionnaire was provided as an Additional
file 1 to the journal and can be find online. While pre-test-
ing the questionnaire, it was verified that it would take
between 15 and 20 min to be completely filled in.
Dependent variables construction
Knowledge
Patient knowledge regarding medicines that have a hazar-
dous influence on driving ability was assessed with respect
to the knowledge about the risk of having a traffic accident
when driving under the influence of driving-impairing
medicines. By using a 5-scale parameter (1 = totally dis-
agree and 5 = totally agree), patients could agree (or dis-
agree) with the following sentences: “t h er i s ko fh a v i n ga
road accident is smaller when you have just started taking
a driving-impairing medicine compared to long term treat-
ment” or “the risk of having a road accident is similar
when you take more of a driving-impairing medicine than
prescribed” or “the risk of having a road accident remains
the same when you use several driving-impairing medi-
cines at the same time.” The internal consistency of the
scale was checked by means of the Cronbach alfa coeffi-
cient (0.64) and the sum score was calculated.
Reported behaviour
Patient reported behaviour was analysed in terms of a
change in their frequency of driving (yes or no) or in
terms of changing the use of driving-impairing medicines
(yes or no). For each questions, the sum score of the dif-
ferent statements was calculated. Table 1 shows the
answers participants provided, as well as the number of
participants that answered each question.
Independent variables construction
The following variables were included in the multi- and
logistic- regression analysis:
￿ Country (Belgium, Germany, the Netherlands and
Spain).
￿ Patient gender and age category (18-25; 26-34; 35-
44; 45-54; 55-64; 65-75. Age category 55-64 was used as
r e f e r e n c ea si ti st h ea g eg r o u pt h a tt a k e sm o r e
medicines).
￿ Educational level (not completed primary school,
completed primary school, lower vocational training,
intermediate vocational training and university degree
entered as dummy variables in the analysis. Intermediate
vocational training was used as reference).
￿ Use of motorised vehicles (participants were consid-
ered as “frequent users” when they used their motorised
vehicle “5-7 days per week” or “2-4 times per week";
“sporadic users” were the ones using a motorised vehicle
“2-4 times per month” or “once a month or less” or
“never.” The scale to assess frequency of driving was pre-
viously used in other studies in this same field [20]).
￿ Experienced side effects that can potentially impair
driving ability such as sleepiness or drowsiness, decrease
of alertness, problems concentrating, blurred vision and
dizziness (yes/no).
￿ Information received from healthcare providers
related with the influence of medicines on driving ability
(yes/no).
￿ Information looked up by patients themselves,
related to the influence of medicines on driving ability
(yes/no).
￿ Whether patients read the Patient Information Leaf-
let (PIL) or not (yes/no). This question did not attempt
to investigate comprehension. Instead, it was used to
know whether patients used the PIL as source of
information.
￿ Patient attitude-In order to assess patient attitudes
towards the use of medicines that potentially impair
patients while driving, a 5-scale parameter (1 = totally dis-
agree and 5 = totally agree) was used to analyse patient’s
opinion in relation with the use of impairing medicines
and driving as well as the consequences of driving under
the influence of impairing medicines. In both cases, the
internal consistency of the scale was checked by means of
the Cronbach alfa coefficient (0.85 and 0.69 respectively)
and the sum score was calculated. To investigate patient
attitude towards the use of impairing medicines, questions
such as “when I drive while using driving-impairing medi-
cines I endanger my personal safety” or “when I have been
prescribed a driving-impairing medicine I choose not to
use my car and choose other types of transportation” or
“when I have been prescribed a driving-impairing medi-
cine, I try to use my car as little as possible” were asked.
Questions such as “the risk of driving under the influence
of driving-impairing medicines is being exaggerated” were
used to address patient attitude towards the consequences
of driving under the influence of impairing medicines.
Data-analysis
Guidelines were developed for all participating countries
in order to ensure that data entry was conducted the
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undefined values and extreme outliers. Data were ana-
lysed using SPSS 16.0 for Windows.
Descriptive analysis was used to report on respondent
characteristics such as gender, age and educational level.
Multiple linear regression analysis was used to identify
patient knowledge about driving while using medicines
that might impair driving ability, whereas reported beha-
viour was analysed by means of multiple logistic regres-
sion. Multiple linear regression analysis could not be used
in both situations because this statistical test is only
applicable when the dependent variable is continuous
(which is the case with investigating participant knowl-
edge). As behaviour is a dichotomous variable (yes/no),
multiple logistical regression was applied in order to pre-
dict which factors influence patient behaviour. Knowledge
and reported behaviour were considered as dependent
variables of the equation. Independent variables, those that
can theoretically influence the dependent variables, con-
sisted of country, gender, age category, educational level,
use of motorised vehicles, self-report of experienced side
effects, information about medicines (either received from
healthcare providers, looked up by patients themselves, or
stated in the PIL), intake of medicines, knowledge itself,
and, finally, attitudes towards use of medicines and driving
and towards driving under the influence. Prior to the con-
struction of the models, univariate analysis of variance was
conducted to verify whether or not there was an interac-
tion effect between the consumption of medicines and age
influencing patients’ knowledge. As no interaction effects
between medicines’ consumption and age were found, it
was decided not to include them, as variables, in the mod-
els. A p-value < 0.05 was considered as statistically
significant.
Results
Data collected from 633 questionnaires (overall response
rate of 18%) were used, as shown in Table 2. Ninety-
three questionnaires that were returned could not be
used for the analysis for several reasons: questionnaires
came back with no answers (54.6%); questionnaires
belonging to patients that did not meet the inclusion cri-
teria (36.4%); and questionnaires with no reference to the
medicines that participants were taking and, simulta-
neously, patients stated not taking any medicine (3.3%).
The relevant characteristics of the study population are
summarised in Table 3. The majority of the respondents
were female and almost 50% of the total population was
Table 1 Statements on changes in reported behaviour, concerning driving ability and use of driving-impairing
medicines
Frequency (4 countries)
Statements on changes in frequency of driving N = 305
Participants decided not to change frequency of driving because:
￿“ I did not think the information was relevant to me"; 25
￿“ It was not feasible for me to change my frequency of driving"; 41
￿“ I did not notice any negative effects that influenced my driving ability"; 108
￿“ I found information stating that the medicine does not have any driving-impairing effects"; 32
￿“ other reasons”. 19
Participants decided to change frequency of driving because:
￿“ I decided not to drive my motorised vehicle anymore"; 17
￿“ I decided to drive/ride a motorised vehicle less often"; 26
￿“ I decided to drive/ride a motorised vehicle on less parts of the day” (e.g. only during day light); 19
￿“ other reasons”. 18
Statements on changes in the use of driving-impairing medicines N = 296
Participants decided not to change the use of driving-impairing medicines because:
￿“ I did not think the information was relevant to me"; 78
￿“ There was no alternative medicine available"; 62
￿“ other reasons”. 46
Participants decided to change the use of driving-impairing medicines because:
￿“ I decided not to use the medicine"; 4
￿“ I decided to use (most of) the medicine at night instead of during the day"; 62
￿“ I decided to only use the medicine when I did not need to drive"; 24
￿“ I asked for or I was prescribed a medicine causing less impairment of the ability to drive”.8
￿“ other reasons”. 12
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Country Number of questionnaires sent
out to pharmacies
Number of
questionnaires
returned
Response
rate (%)
Number of questionnaires used in the analysis (after
screening the inclusion criteria)
Belgium 1000 144 14.4 136
Germany 880 162 18.4 146
The
Netherlands
830 150 18.1 136
Spain 960 270 28.1 215
Total 3670 726 17.75
(mean)
633
Table 3 Characteristics of the respondents, per country
Country p-value*
Belgium Germany Netherlands Spain
Total number of participants 136 146 136 215
n%
a n%
a n%
a n%
a
Gender
Male 135 34.6 145 34.2 136 41.2 214 47.0 0.175
Female 64.7 65.1 58.8 52.6
Age Category
18-25 5.9 1.4 3.7 6.5
26-34 134 11.8 145 10.3 136 5.9 213 20.5 < 0.001*
35-44 18.4 24.7 26.5 27.0
45-54 32.4 21.2 23.5 22.8
55-64 15.4 19.2 27.2 14.0
65-75 14.7 22.6 13.2 8.4
Educational level
Not completed primary education 11.0 0.7 1.5 5.1
Completed primary education 14.7 32.2 5.9 19.1
Lower vocational training 132 22.8 145 32.2 128 19.1 215 16.7 < 0.001*
Intermediate vocational training 25.7 17.8 41.9 19.5
University 22.8 16.4 25.7 39.5
Use of motorised vehicles
Sporadic users 136 33.1 146 34.9 136 47.8 215 31.2 0.012*
Frequent users 66.9 65.1 52.2 68.8
Use of driving-impairing medicines
Use of 1 medicine 65.2 70.8 71.2 75.0
Use of 2 medicines 28.1 25.0 23.5 21.2
Use of 3 medicines 135 5.9 144 4.2 132 4.5 212 2.8 0.734
Use of 4 medicines 0.7 0.0 0.8 0.9
Experienced side effects
No 132 51.5 146 48.6 134 37.3 211 29.9 < 0.001*
Yes 48.5 51.4 62.7 70.1
Knowledge
b
About the risk of having a road accident when using medicines
c 2.4 (1.0) 2.4 (1.1) 2.3 (1.0) 2.3 (0.9) 0.882
Attitude
b
Use of medicines and driving
c 2.3 (0.9) 2.8 (1.4) 1.9 (0.8) 2.1 (1.1) < 0.001*
Consequences of driving under the influence of impairing medicines
d 3.5 (0.9) 4.0 (0.9) 3.4 (0.9) 3.6 (0.8) < 0.001*
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there is a slightly higher number of patients with a uni-
versity degree (27.6%) compared to other levels of educa-
tion. Another relevant characteristic of participants is
how often they use motorised vehicles. Participants of
our study were mainly frequent users of motorised vehi-
cles, meaning they used their car on a daily or weekly
basis.
Concerning self-reported medication that patients were
taking, within countries, antidepressants were the most
stated medicines (42.0%; n = 266) followed by anti-aller-
gics (36.2%; n = 229), sedatives (27.5%; n = 174), and
tranquilisers (26.5%; n = 168). Figure 2 shows the percen-
tage of self-reported use of medicines. Antidepressants
are the most frequently used group of medicines in each
country except in Spain, where there is a higher percen-
tage of anti-allergics and where there is a homogenous
prevalence of consumption of sedatives, tranquilisers,
and antidepressants. In the Netherlands, the prevalence
of use of anti-allergics is the lowest. Only in Belgium is
t h et r e n do fu s eo fm e d i c i n e st h es a m ea ss e l f - r e p o r t e d
medication. An average of medication use in the 4 coun-
tries shows that patients took 1.32 medicines. 71.1% (n =
443) of the patients stated that they were taking only one
medicine category at a time, and 0.6% (n = 4) of the
patients combined all four medicine categories.
With regard to side effects, 40.4% (n = 252, Table 3)
of patients stated that they did not experience any type
Table 3 Characteristics of the respondents, per country (Continued)
Reported behaviour - change in the frequency of driving
No 42 61.9 64 71.9 79 81.0 120 74.2 0.149
Yes 38.1 28.1 19.0 25.8
Reported behaviour - change in the use of driving-impairing medicines
No 38 57.9 65 55.4 75 81.3 118 56.8 0.002*
Yes 42.1 44.6 18.7 43.2
aThe percentage refers to within the country
bKnowledge and attitude results presented in terms of mean (standard deviation)
c5-item scale (1 = totally disagree; 2 = disagree; 3 = no opinion; 4 = agree; 5 = totally agree). Totally disagree means that the patient does not perceive any risk
of driving under the influence of medicines
d5-item scale (1 = totally disagree; 2 = disagree; 3 = no opinion; 4 = agree; 5 = totally agree). Totally disagree means that patients have a negative opinion on
the influence of medicines on driving performance and about the consequences of that behaviour
* p-value < 0.05 considered to be statistically significant. P-value was calculated by means of the Chi-square test.
Figure 2 Self-reported use of medicines by respondents per country (percentage within country).
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patients who experienced side effects was higher than
those who did not. From those who experienced side
effects, “sleepiness” (24.1%) was most often stated, fol-
lowed by “decrease in alertness” (12.7%), “problems con-
centrating” (10.6%), “dizziness” (5.8%), and “blurred
vision” (4.2%). For all studied medicines, relevant side-
effects were all listed in the PIL, which is accessible to
patients and was read entirely by 55.8% (n = 348) of the
respondents; 30.6% (n = 191) of patients read only parts
of the PIL.
In Belgium, the percentage of patients stating they
w e r en o ti n f o r m e dw a sh i g h e r ,t h o u g hn o ts i g n i f i c a n t l y
than any other country. 63.6% (n = 84) of Belgian parti-
cipants did not receive this information. Considering the
four countries together, 62.5% (n = 349) of the patients
received information from healthcare providers.
Patient knowledge about the risk of having a road
accident was similarly low in all countries (Belgium and
Germany 2.4 and the Netherlands and Spain 2.3 on
average on a 5-item scale, where 5 is the highest score).
Regarding reported behaviour (Table 3), 26.2% of
patients were in favour of a change in driving frequency,
while 37.2% were in favour of a change in the use of
driving-impairing medicines. In terms of attitude
towards the use of medicines while driving, patients dis-
agreed with the statements that were presented in Bel-
gium (average of 2.3), in the Netherlands (average of
1.9) and in Spain (average of 2.1); in Germany, patients
did not have an opinion (average of 2.8). With respect
to the attitudes towards driving under the influence of
medicines, only German patients agreed (average of 4.0)
with the fact that the risk of driving under the influence
of medicines was exaggerated.
Knowledge
Multiple linear regression analysis was used to assess fac-
tors influencing patient knowledge (Table 4) towards driv-
ing-impairing medicines. As previously mentioned,
knowledge was considered in terms of risk of having a
road accident. From Table 4, it is clear that independent
variables explain 10.6% (adjusted R
2) of the differences
found between patients. The age of the patient is corre-
lated with the knowledge about the risk of being involved
in a traffic accident: the younger the patient the greater
the knowledge about the risk. Regarding educational level,
knowledge is higher among patients with an academic
degree. Information patients received from healthcare pro-
viders, looked-up by patients themselves, or the informa-
tion stated in the PIL did not appear to contribute to
patient knowledge. The use of motorised vehicles had no
effect on patient knowledge. Self-report of experience of
side effects was also not significant.
Reported behaviour
Multiple logistic regression was performed to assess the
impact of patient reported behaviour with respect to
changes in frequency of driving and the use of driving-
impairing medicines (Table 5). The independent vari-
ables explain 34.8% and 27.3% (adjusted R
2)o ft h ev a r -
iance for changes in driving frequency and in the use of
driving-impairing medicines, respectively. Patients were
more likely to change their frequency of driving when
they are between 26 and 34 years old, when they report
side effects, and when they have a negative attitude
towards driving under the influence of impairing medi-
cines. In contrast, patients who drive frequently and
those who take anti-allergics tend to change their driv-
ing frequency less often compared to users of tranquili-
sers (Table 5). Concerning the model that takes into
account changes in the use of driving-impairing medi-
cines, patients who reported having experienced side
effects and those who have knowledge about having a
traffic accident appeared to change the use of driving-
impairing medicines more often than those who came
from the Netherlands or those who take antidepressants
(Table 5).
Discussion
The present survey showed that socio-demographic vari-
ables, such as age and educational level, influenced patient
knowledge about causes of road accidents: younger and
higher educated patients had better knowledge. Informa-
tion that might have been provided to or accessed by
patients contributed to patient knowledge regarding the
risk of having a traffic accident. In contrast, patient
reported behaviour did not appear to be influenced by any
of the socio-demographic variables considered in the ana-
lysis. Instead, frequency of driving changed due to experi-
ence of side effects and attitudes towards driving under
the influence of driving-impairing medicines. The use of
motorised vehicles and intake of anti-allergic medicines
had less influence on the frequency of driving. Regarding
changes in the use of driving-impairing medicines, our
model suggested that such changes were mainly influ-
enced in a positive manner (meaning a change in reported
behaviour) by experienced side effects and knowledge
about the risk of having a road accident and negatively
influenced by country (specifically The Netherlands) and
by the use of anti-depressant medicines.
Among the 4 participating countries, self-reported
medication use indicated that patients took, on average,
1.3 medicines that are known to be driving-impairing.
For antihistamines [21] and antidepressants [22], a dose-
dependent negative effect on driving was found in road-
side tests previously conducted in the Netherlands.
Nevertheless, patients still drive their car (or any other
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Page 8 of 13motorised vehicle) on a daily basis, which could be
explained by the fact that they no longer experience side-
effects. This is supported by previous research showing
that an increased number of patients using psychotropic
medicines regularly do not refrain from driving their car
[23].
Sleepiness, decrease in alertness, problems concentrat-
ing, dizziness or blurred vision were reported at least one
time during treatment by almost 60% of the participants.
These side effects are presumed to be potentially danger-
ous for driving ability [15]. However, experiencing side
effects does not seem to be enough to make patients quit
driving. At best, experiencing side effects will change
patients’ frequency of driving. This could indicate that
patients tend to underestimate the risk that is associated
with driving under the influence of medicines [15] and
that their knowledge about medicines’ side effects is lim-
ited [14] or that the side effects occurred at other times
than when they were driving. On the other hand, a fair
percentage (40%) of patients did not report any side
effects. This could be explained by the long term use of
medicines (a requirement to be included in the study; see
criteria inclusion section)., which may result in the devel-
opment of a tolerance to the side effects [23], or by the
relationship between medicine use and side effects, for
example in Spain 70.1% of patients stated having experi-
enced side effects, which can be related with the high
prevalence (40.9%) of use of first generation anti-allergic
medicines.
Knowledge
Much of patients’ knowledge regarding medicines and
side effects, in general, comes from communication with
their general practitioner [14,15]. Similar to the existing
literature, the present study shows that the majority of
the participants received information about the
Table 4 Predictors for patient knowledge on risks of having a road accident: multiple linear regression analysis
Risk of having road accidents
(N = 617)
Independent variables Standardised coefficients (p-value)
Constant 3.469
Country (Germany used as reference) -
Belgium 0.02 (0.798)
The Netherlands 0.00 (0.982)
Spain -0.04 (0.529)
Gender (0 = male; 1 = female) -0.03 (0.487)
Age categories (category 55-64 used as reference) -
18-25 0.07 (0.134)
26-34 0.10 (0.048)*
35-44 0.16 (0.005)*
45-54 0.09 (0.092)
65-75 -0.13 (0.010)*
Educational level (Intermediate vocational training used as reference) -
Not completed primary school -0.14 (0.002)*
Completed primary school -0.03 (0.621)
Lower vocational training -0.05 (0.297)
University 0.18 (< 0.001)*
Use of motorised vehicles (0 = sporadic users; 1 = frequent users) -0.04 (0.330)
Experienced side effects (0 = no side effects; 1 = side effects) 0.05 (0.283)
Information received from healthcare providers
(0 = no information was provided; 1 = information was provided)
0.00 (0.970)
Information looked for patients
(0 = no information was looked for; 1 = information was looked for by patients)
0.00 (0.927)
Information from the PIL
(0 = patients don’t read the PIL; 1 = patients read the PIL)
0.01 (0.893)
Adjusted R
2 0.106
F 4.477
p-value (model) < 0.001*
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Page 9 of 13Table 5 Changes in driving frequency and in use of driving-impairing medicines: multiple logistic regression analysis
Independent variables Change in driving frequency (n =
305)
Change in the use of driving-impairing medicines
(n = 296)
Odds-ratio 95% CI for OR Odds-ratio 95% CI for OR
lower upper lower upper
Country (Germany used as reference)
Belgium 2.00 0.53 6.41 0.79 0.29 2.19
The Netherlands 0.69 0.21 2.26 0.24* 0.08 0.69
Spain 0.63 0.23 1.72 0.46 0.20 1.07
Gender (0 = male; 1 = female) 1.70 0.97 3.00 1.18 0.77 1.80
Age categories (category 55-64 used as reference)
18-25 4.87 0.93 25.49 0.81 0.18 3.52
26-34 4.17* 1.14 15.25 1.78 0.59 5.42
35-44 2.08 0.71 6.15 1.72 0.68 4.31
45-54 2.75 0.97 7.84 1.79 0.71 4.54
65-75 1.62 0.48 5.84 0.60 0.19 1.95
Educational level (Intermediate vocational training used as reference)
Not completed primary school 1.14 0.17 7.65 0.76 0.14 4.15
Completed primary school 2.78 0.95 8.11 2.13 0.81 5.61
Lower vocational training 2.20 0.82 5.90 0.79 0.33 1.88
University 1.46 0.57 3.71 0.98 0.43 2.20
Use of motorised vehicles
(0 = sporadic users; 1 = frequent users) 0.35* 0.18 0.69 0.58 0.31 1.10
Experienced side effects
(0 = no side effects; 1 = side effects) 3.18* 1.40 7.21 3.39* 1.68 6.82
Medicines (Tranquilisers used as reference)
Sedatives 0.77 0.36 1.62 1.07 0.55 2.08
Antidepressants 0.84 0.42 1.68 0.24* 0.12 0.50
Anti-allergics 0.24* 0.10 0.58 0.82 0.40 1.66
Knowledge about the risk of having a road accident (0 = totally disagree; 5 = totally agree) 0.932 0.65 1.33 1.49* 1.09 2.03
Attitude
Use of medicines and driving (0 = totally disagree; 5 = totally agree) 0.88 0.64 1.20 1.08 0.82 1.43
Driving under the influence of driving-impairing medicines (0 = totally disagree; 5 = totally agree) 2.23* 1.43 3.50 1.29 0.91 1.85
Adjusted R
2 0.348 0.273
p-value (model) < 0.001* < 0.001*
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3influence of their medicines on their ability to drive
from healthcare providers (both general practitioners
and community pharmacists). The only exception was
seen in Belgium, where more than 60% of the partici-
pants stated not having been informed about medicines
and driving. Several studies [24,25] concluded that the
communications between clinicians and patients about
the potential risk of medicines is often incomplete. If so,
it is crucial to increase physician awareness of poten-
tially driving-impairing medicines in order to improve
the communication with patients who could benefit
from better and more complete counselling.
The information that patients received from health-
care providers, or that patients looked up themselves,
did not appear to be effective enough to influence
patient knowledge regarding the risk of being involved
in a traffic accident. This is in line with previous
research where it is shown that patients who are at a
greater risk of being involved in a traffic accident due to
medicines do not necessarily have more knowledge of
increased risk [15]. Age and educational level appear to
be the only two variables capable of influencing patient
knowledge about the risk of having a road accident.
Younger patients and patients with a higher educational
level seem to have a greater health literacy (knowledge)
and, as a consequence, a bigger awareness of the danger
of using medicines and driving than older patients and
those with lower educational level. The theoretical
model that was developed (Figure 1) is supported by the
findings concerning knowledge, as socio-demographic
characteristics had both a positive and negative impact
on patient knowledge.
Reported behaviour
Age is the variable with a greater positive impact in the
model: participants between 26 and 34 years-old are the
ones more likely to change their driving behaviour.
Patient self-report of side effects also correlates positively
with changes in frequency of driving; this means that
patients who felt side effects are more likely to change
their driving behaviour. The same holds true for attitude
towards driving under the influence of medicines. This
variable positively influences the model, meaning that
patients with a stronger attitude towards the conse-
quences of driving under the influence are the ones chan-
ging the frequency of driving. Conversely, the use of
motorised vehicles influences patient reported behaviour
negatively, i.e. the more patients drive the less they
change their driving behaviour in terms of frequency of
driving. The use of anti-allergic medicines also correlates
negatively with the model, making patients taking these
medicines less prone to change their frequency of driv-
ing. This could be due to the fact that patients might not
be aware that anti-allergic medication has a negative
effect on driving ability or that side-effects occur when
the patient is not driving. Another explanation for this
fact could be due to the less sedative effect of the 2nd
generation antihistamines, and, therefore, patients do not
recognize any signs of impairment on their psychomotor
abilities and, as a consequence, patients feel safe to drive.
Living in the Netherlands, experiencing side effects,
using antidepressants, and knowledge about the risk of
having a traffic accident are the factors that significantly
account for changes in the use of medicines. Patients liv-
ing in the Netherlands and using antidepressant medi-
cines change the use of medicines less often. This could
be due to the fact that antidepressants are well known to
affect driving. As a consequence, healthcare providers,
such as physicians or pharmacists, can immediately pro-
vide patients with preventive measures (for example, tak-
ing the medicines at night), which might reduce the
negative effects of the medicines on driving ability result-
ing in a less need to change driving frequency.
In contrast, self-report of experiencing side effects and
knowledge about risk of being involved in a road accident
contribute positively to change in the use of driving-
impairing medicines. This means the more side effects a
patient experiences and the greater their knowledge
about the side effect, the bigger the chances that they will
change the intake of their medicines.
Similarly to knowledge, the findings on predictors for
patients’ reported behaviour support the theoretical
model developed. Reported behaviour is not always
influenced by the same range of variables, meaning that
behavioural actions result from a combination of differ-
ent factors that ultimately lead to an action.
Limitations and future perspectives
The results of this study should be considered in the light
of several strengths and limitations. The major limitation
of this study is the low response-rate, in all 4 participat-
ing countries. As a consequence, results should be con-
sidered with care and conclusions should be drawn with
caution, as the results might not be representative of the
whole driving population that takes driving-impairing
medicines. However, the actual number of questionnaires
that was handed out to patients was not known but the
authors believe it was smaller than 3607, meaning that
the actual response rate could be higher than 18%. There
could be, as well, a potential selection bias. To ensure
that only data referring to patients who met the inclusion
criteria were part of the analysis, the survey included
questions covering the inclusion criteria. Nevertheless,
the authors are confident that it is possible to draw rele-
vant conclusions.
Main results were achieved based on patient self-report
of medicine use, and knowledge, attitude and behaviour
related with medicines and driving. Self-report is a widely
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Therefore, the authors trust that the information stated
by patients concerning consumption of medicines is in
line with pharmacy dispensing records [15] and the same
stands true for self-report behaviour that is known to be
an accurate proxy for observed behaviour [27]. With the
present study, it was possible to determine which vari-
ables and to what extent they influence patient knowl-
edge and reported behaviour towards medicines that
influence driving ability in 4 European countries. In addi-
tion, given the fact that especially the explained variance
for knowledge is quite low (10.6%), other variables, such
as health literacy, history of car accidents, or ethnicity
may play an important role in patient knowledge and
reported behaviour and should be considered in further
research.
To our knowledge, only one American study [15]
addressed the problem of knowledge about medicines
that can impair driving. However, the study conducted
by MacLennan et al. was very much oriented to the
knowledge that older adults who face serious driving
safety and mobility issues have. The present study
attempts to reflect knowledge and reported behaviour of
a much broader and heterogeneous population, which
makes it relevant for the field of medicines and driving
and traffic safety. By accessing predictors for patient
knowledge and reported behaviour, it is possible to
develop more effective campaigns that point out exactly
what is relevant for the patients, i.e. campaigns tailored
to the patients’ needs. At the same time, it is possible to
give positive feedback to patients who already possess
good knowledge (and therefore do not need to change)
and also to help patients’ with making decisions of
whether they should drive their car or not while taking
driving-impairing medicines.
Future research should not only focus on information
campaigns for patients but also for healthcare providers.
Interventions that might raise awareness about the topic
and might improve communication with patients about
the risk of driving under the influence of psychotropic
medicines are important topics for future research, as
well. As current information does not effectively contri-
bute to patient knowledge, the authors believe there is
the need for more effective ways to communicate infor-
mation to patients, which might be capable of increasing
patient knowledge and changing patient attitudes
towards driving under the influence of medicines. New
strategies to enhance communication could make use of
pictograms on the box of medicines that are known to
impair driving fitness. Well designed pictograms are
known to improve comprehension and recall of infor-
mation and can be used to trigger the discussion
between healthcare providers and patients. This could
potentially contribute to increasing the patient’s
knowledge about the use of medicines that might affect
driving fitness.
Finally, research can also contribute to develop, imple-
ment, and evaluate guidelines and other information
materials and/or tools that aim to provide decision sup-
port to physicians and pharmacists in prescribing and
dispensing potentially impairing medicines. Additionally,
the information provided to patients during the consul-
tation can be improved if healthcare providers know
how to advise their patients, which leads to the conclu-
sion that the advice to the patient should be part of the
developed information materials as well. Without a
doubt, this is also a task for implementers or policy
makers.
Conclusions
Patient knowledge regarding driving under the influence
of medicines does not predict changes in driving beha-
viour. Rather, negative attitudes towards driving under
the influence of medicines is a better predictor of
changes in patients’ driving behaviour.
Patients’ knowledge is influenced by socio-demo-
graphic parameters such as age and educational level.
Behavioural changes can be explained both in terms of
changes in frequency of driving and in terms of changes
in the use of driving-impairing medicines. Patients who
experienced side effects and who have negative attitudes
towards driving under the influence of impairing medi-
cines are more prone to change their driving behaviour
(positive influence in behaviour) than those who use
motor vehicles on a daily basis or those who use anti-
allergic medicines. Patients who experienced side effects
and who have a good knowledge of risks of having road
accidents seem to change the use of driving-impairing
medicines more easily than those who come from the
Netherlands or take antidepressant medicines.
Future research should focus on more effective ways to
increase patient knowledge and to help patients’ decision
making towards driving behaviour and medication intake.
T h i sc o u l db ed o n eb yi m p l e m e n t i n gn e ws t r a t e g i e so f
communication in order to prevent patients from driving
under the influence of medicines. Special attention
should be paid to healthcare p r o v i d e r sa st h e ya r et h e
main source of information for patients. By increasing
healthcare provider awareness about medicines and driv-
ing, we believe that patient knowledge will also increase
and as a consequence could be responsible for a decrease
in patients’ driving frequency or a stabilisation in patient
behaviour regarding changes in the use of medicines.
Additional material
Additional file 1: Questionnaire for patients. The use of medicines in
traffic.
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